Last updated: March 3, 2026
Sponsor: NYU Langone Health
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Heart Disease
Cardiomyopathy
Congestive Heart Failure
Treatment
Tako Breath
Clinical Study ID
NCT03324529
17-00868
Ages > 21 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Confirmed history of takotsubo syndrome
Healthy person with no significant past history of cardiovascular or neurologicaldisease such as heart failure or heart attack; people with cardiovascular riskfactors such as hypertension will be permitted to participate
Exclusion
Exclusion Criteria:
Pacemaker or defibrillator implanted
Evidence of autonomic neuropathy, alcohol or drug abuse or exposure to neurotoxins (chemotherapy).
Diabetes
Study Design
Total Participants: 24
Treatment Group(s): 1
Primary Treatment: Tako Breath
Phase:
Study Start date:
October 01, 2021
Estimated Completion Date:
June 30, 2027
Connect with a study center
New York University School of Medicine
New York, New York 10016
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.